Search
Filter Results
Displaying 651–660 of 851 results for “vision connection”
-
Jul 10, 2019
Beacon Stories My Retina Tracker Patient StoriesSusan, who has retinitis pigmentosa, went through many tests in search of learning more about her eye disease. Once she enrolled in the My Retina Tracker® (MRT) testing program, Susan was provided with comprehensive results and a clear diagnosis, giving her clarity and hope.
-
Jun 21, 2019
ResourceDr. Jacque Duncan, UCSF Professor of Clinical Ophthalmology, is currently working on therapies restoring vision for retinal degenerative diseases. Dr. Duncan has hope and optimism for the future that vision will be restored for those with retinal diseases, thanks in part by the Foundation’s work.
-
Jun 17, 2019
Jack Sees a Different Life after LUXTURNA
Beacon StoriesJack Hogan was diagnosed with retinitis pigmentosa at only two-and-a-half years old. But with the help of connections made with the Foundation, Jack became the first-ever recipient of the FDA-approved gene therapy known as LUXTURNA.
-
Jun 3, 2019
Original Foundation Advocate Gertrude Weiss Celebrates 100th Birthday
Beacon StoriesGertrude Weiss was one of the early Foundation Fighting Blindness investors and advocates. Diagnosed with retinitis pigmentosa, Gertrude continues to live her life to the fullest. As a longtime friend, the Foundation honored Gertrude on her 100th birthday recently.
-
May 20, 2019
Dr. Don Zack Honored for Research Contributions by ARVO and the Foundation Fighting Blindness
Research NewsDr. Zack is a member of the Foundation’s Scientific Advisory Board and chairs its Cellular Molecular Mechanisms of Disease study section.
-
-
-
Apr 26, 2019
Legally Blind Artist Paul Castle Expresses His Story through Art
Beacon StoriesPaul Castle was diagnosed with X-linked retinitis pigmentosa at the age of 16, but continued to follow his passion for art. Now Paul is a full-time artist and donates 5 percent of his art sales to the Foundation.
-
-
Apr 16, 2019
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
Research NewsThe treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10